Category: cell therapy

In the ever-evolving landscape of cancer immunotherapy, the emergence of bispecific antibodies (BsAbs) presents a promising avenue for the treatment of B-cell lymphomas. Unlike traditional monoclonal antibodies, BsAbs target both tumor-associated epitopes and components within the T-cell receptor complex, offering a novel approach to redirect T cells to eliminate cancerous cells. Recently, a panel of […]

Chronic lymphocytic leukemia (CLL) treatment landscape has undergone a remarkable evolution with the emergence of targeted combinations, cellular therapies, and bispecific antibodies. This transformation has steered away from traditional chemoimmunotherapy towards more refined treatment strategies tailored to individual patient needs and disease characteristics. The convergence of double and triple combination therapies, alongside novel agents like […]

In the realm of battling the formidable foe of diffuse large B-cell lymphoma (DLBCL), a groundbreaking discovery has emerged to wield the power of predictability in the efficacy of chimeric antigen receptor (CAR) T-cell therapy. The conventional PET biomarkers, long-standing soldiers in the fight against this relentless disease, have met their match in a PET-based […]

Researchers are propelling CAR T therapy beyond blood cancers into uncharted territory, exploring its potential in treating clear cell renal cell carcinoma, a challenging form of kidney cancer. Dr. Wayne A. Marasco and his team have made significant strides by developing a groundbreaking dual-targeting CAR T-cell therapy for patients with advanced kidney cancer expressing high […]

In the realm of innovative cancer therapies, the spotlight shines on the groundbreaking chimeric antigen receptor natural killer (CAR NK) cell therapy, a beacon of hope for patients battling acute myeloid leukemia (AML). Dr. Stephen Strickland, a luminary in Leukemia Research at the Sarah Cannon Research Institute, recently unveiled the remarkable potential of SENTI-202, a […]

In the realm of cancer treatments, the development of chimeric antigen receptor (CAR) therapies has revolutionized the landscape, particularly in blood cancers. While CAR T-cell therapy has been instrumental in saving lives, its customized nature poses challenges in terms of timely availability for certain patients. In acute myeloid leukemia (AML), a rapidly progressing disease requiring […]

Your AI-Trained Oncology Knowledge Connection! Exploring BPDCN Long-Term Data In a recent live event, Dr. Taha Al-Juhaishi delved into the extended outcomes of treating blastic plasmacytoid dendritic cell neoplasm (BPDCN), shedding light on the path to achieving durable complete responses (CRs) and the role of transplants in the process. The Evolution of BPDCN Treatment Recognition […]

Cellares, a prominent player in the cell therapy manufacturing industry, has taken a significant stride forward with its groundbreaking Cell Q platform. This innovative technology, introduced in 2024, stands out as the first fully automated system designed specifically for cell therapy quality control. The strategic partnerships recently announced by Cellares with leading technology providers signify […]

In a groundbreaking study, scientists at the University of Zurich have made a remarkable breakthrough in stroke recovery by utilizing stem cell therapy to repair stroke damage in mice. This innovative approach holds the potential to revolutionize stroke recovery treatments and offer hope to millions of individuals affected by the debilitating consequences of stroke. The […]

In the intricate realm where science and medicine converge, a tapestry of issues and controversies often unfolds, offering a glimpse into the complexities underlying innovative treatments. Stem cell therapy, a beacon of hope in regenerative medicine, has not been immune to the allure of premature hype and fraudulent practices that have tarnished its potential. The […]

In the captivating realm of regenerative medicine, one of the most promising avenues lies in umbilical cord blood (UCB) banking. Stem cells sourced from UCB are a beacon of hope for individuals battling various diseases, offering a wellspring of ethnically diverse stem cells that can be used for transplantation. The journey of UCB transplantation began […]

Are you tired of letting knee pain hold you back from living your best life? Look no further! Dr. Abraham An, the esteemed leader of Lydian Cosmetic Surgery Clinic, a pioneer in stem cell therapy and regenerative medicine in South Korea, is here to revolutionize your knee health game! The Breakthrough Knee Pain Treatments You’ve […]

Genetically stable multi-gene edited iPSCs-derived NK cells are a groundbreaking innovation for cancer immunotherapy. Kang and colleagues have pioneered a platform technology combining cellular reprogramming, gene editing, and differentiation techniques to create upCAR-iPSCs and upCAR-NK cells. This development opens the door to a full-off-the-shelf anti-cancer immune cell therapy with enhanced efficacy, reduced side effects, and […]

Are you ready to dive into the cutting-edge world of cellular immunotherapy? Buckle up as we explore the groundbreaking research on CD70-targeted induced pluripotent stem cell-derived CAR-natural killer (NK) cells, a game-changer in the fight against tumors and alloreactive T cells. The realm of cancer treatment has long been plagued by challenges such as limited […]

In the realm of cancer treatment, the emergence of immunotherapy utilizing chimeric antigen receptors (CARs) has brought about a significant shift in the therapeutic landscape, offering new avenues of hope where traditional treatments have fallen short. Among these novel approaches, CAR-natural killer (NK) cells stand out as a promising strategy. These engineered NK cells, armed […]

BlueWhale Bio, a biotech start-up founded by Perelman School of Medicine professors Carl June and James Riley, has recently launched a groundbreaking patient trial for cancer immunotherapy. This trial, utilizing the Synecta platform developed by BlueWhale Bio, aims to test the safety and feasibility of huCART19-IL18 cells, a cutting-edge fourth-generation CAR T-cell therapy, in treating […]

In an effort to bolster research and development in Massachusetts, Governor Maura Healey has unveiled the Discovery, Research, and Innovation for a Vibrant Economy (DRIVE) initiative. This groundbreaking proposal, if approved, will allocate a substantial $400 million in state funding towards advancing scientific endeavors within the region. Governor Healey recently paid a visit to the […]

Introduction Chimeric antigen receptor (CAR) T-cell therapies have marked a significant breakthrough in treating blood-based malignancies. While the potential of CAR T therapy as a primary or secondary treatment option is becoming increasingly evident, challenges in manual manufacturing processes have led to delays in providing these life-saving therapies to patients promptly. The demand for CAR […]

A recent review conducted by the European Society for Regenerative Medicine shed light on the safety and efficacy of stem cell therapy, particularly with mesenchymal stromal cells (MSCs), in treating chronic pain and degenerative conditions. This comprehensive analysis of over 70 clinical trials showcased the potential of stem cell therapies for addressing ailments such as […]

Embarking on the intricate path of advanced therapies in cell therapy and regenerative medicine is a journey filled with both scientific marvel and regulatory complexities. As we delve into the world of cell therapies, tissue engineering, and gene therapy, we uncover a realm where the potential for transformative therapeutic applications meets the stringent demands of […]

Clade Therapeutics, a pioneering biopharmaceutical company, has made a significant move in the field of cell therapy by acquiring Gadeta B.V., a leader in developing gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients. This acquisition not only expands Clade’s pipeline but also enhances its platform with the groundbreaking g/d TCR universal targeting platform technology. […]

Introduction Small cell lung cancer (SCLC) represents a formidable challenge in the realm of oncology, characterized by its aggressiveness and high mortality rates. Accounting for 15% of all lung cancer cases, SCLC has long been associated with limited treatment options and a grim prognosis. However, recent breakthroughs in medical science herald a new dawn for […]

Immune cell therapies have emerged as a groundbreaking approach in treating various diseases, including cancers, autoimmune disorders, and infectious diseases. Central to the manufacturing of these therapies is the process of viral transduction, which facilitates the introduction of therapeutic genes into immune cells. The optimization of viral transduction processes poses significant challenges due to the […]

Ciara and Russell Wilson’s journey into advocating for stem cell therapy shines brightly as a beacon of hope and compassion in the realm of pediatric cancer treatment. The power couple, known for their philanthropic endeavors and commitment to making a positive impact, have a heartwarming story to share about how stem cell therapy played a […]

Neurodegenerative diseases such as Parkinson’s and Alzheimer’s present significant challenges in treatment, with current therapies mainly focusing on symptom management rather than restoring lost brain connections. Stem cell therapy has long been viewed as a promising solution due to the potential of stem cells to transform into neurons. However, the delivery of stem cells to […]

Booking Health Expands Access to Dendritic Cell Therapy After Study Confirms Survival Benefit in Glioblastoma Patients In a significant move to broaden patient access to cutting-edge treatments, Booking Health, a prominent medical travel platform based in Langenfeld, Germany, has announced the expansion of dendritic cell immunotherapy for recurrent glioblastoma. This decision follows the release of […]

In the realm of oncology, recent breakthroughs in multiple myeloma therapy have shed light on the potential of trispecific antibodies such as JNJ-5322 to significantly enhance patient outcomes. The field of multiple myeloma treatment has undergone a remarkable transformation over the past few decades, transitioning from traditional chemotherapy to the era of targeted therapies, immunotherapies, […]

iRegene Therapeutics, a pioneering biotechnology company based in Chengdu, China, recently announced the successful completion of its Series B+ financing round following the Fast Track Designation (FTD) granted by the U.S. FDA for its flagship product, NouvNeu001. This milestone makes NouvNeu001 the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive such recognition. […]

The IMPACCT Real-World Evidence Summit West is a crucial event for those looking to stay at the forefront of evidence generation in healthcare. With the increasing importance of real-world data and the integration of AI-powered insights, this summit offers a platform for cross-functional collaboration and practical strategies to leverage technologies for demonstrating treatment value beyond […]

A recent survey conducted by Dutch tech giant Royal Philips has shed light on the differing perspectives regarding the potential of artificial intelligence (AI) in the field of cardiology. The survey highlighted a significant “trust gap” between cardiac care professionals and patients when it comes to the perceived value of AI in improving cardiac care […]

The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Hope Biosciences for their adipose-derived mesenchymal stem cell (HB-adMSC) treatment targeting relapsing-remitting multiple sclerosis (RRMS). This designation follows positive outcomes from a Phase II trial conducted by the Hope Biosciences Research Foundation (HBRF) in 2023 and 2024. The study, […]

ExCellThera has recently obtained conditional marketing authorization from the European Commission (EC) for its Zemcelpro cell therapy, designed to address the needs of adults with haematological malignancies requiring allogeneic stem cell transplants. This approval, granted to ExCellThera’s subsidiary, Cordex Biologics, signifies a significant advancement in providing treatment for blood cancer patients who lack suitable donor […]

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) presents a challenging scenario with limited treatment options, but promising outcomes can be achieved through a combination of achieving remission and undergoing allogeneic hematopoietic cell transplant (HCT). Dr. Taha Al-Juhaishi, an expert in the field, shared insights during a Case-Based Roundtable event, highlighting the significance of regimens such as […]

Gilead Sciences has received approval from the European Union to market its innovative twice-yearly pre-exposure prophylaxis (PrEP) product, lenacapavir, under the brand name Yeytuo. This capsid inhibitor is a first-in-class drug aimed at reducing the risk of sexually acquired HIV-1 in adults and adolescents at increased risk of HIV who weigh at least 35kg. Despite […]

The 3rd Cell Therapy for Autoimmune Disease Summit is set to take place in Philadelphia this December, showcasing groundbreaking studies that demonstrate the potential of cell therapies in achieving lasting remission for autoimmune diseases like lupus. With a focus on bringing the first approved autoimmune cell therapy to the market, over 130 scientific pioneers will […]

Ravi Vij, MD, MBA, sheds light on the impact of insurance-related delays in the approval process for CAR T-cell therapy, which not only hinder prompt treatment initiation but also escalate interim therapy costs and burdens on patients, particularly those battling aggressive blood cancers. The access to chimeric antigen receptor (CAR) T-cell therapy, crucial for many […]

Bayer has submitted a novel MRI contrast agent named Gadoquatrane to the FDA for review. This agent is designed to address concerns associated with gadolinium, a rare earth metal used in current contrast agents that can have negative health and environmental impacts. Gadoquatrane is being evaluated for use in contrast-enhanced MRI scans of the central […]

Germany and Austria have become the inaugural European Union countries to witness the launch of Leqembi, an Alzheimer’s drug developed by Eisai and Biogen after facing significant delays. Leqembi, an anti-amyloid antibody also known as lecanemab, made its debut in Austria and is set to be introduced in Germany, marking the first drug in its […]

Netherlands-based company, Argenx, has recently released encouraging top-line results from the ADAPT SERON trial of its flagship drug, Vyvgart (efgartigimod), designed for treating generalised myasthenia gravis (gMG). The data indicates the drug’s effectiveness in AChR-Ab seronegative patients, a subgroup constituting approximately 20% of gMG patients who have historically had limited treatment options. gMG, an autoimmune […]

Marker Therapeutics recently shared an update on the Phase 1 APOLLO study that focused on MT-601, a Multi-Antigen Recognizing (MAR)-T cell product, for patients with lymphoma who have relapsed post anti-CD19 CAR-T cell therapy or cannot undergo such treatment. The company restructured its clinical programs last year, giving priority to MT-601, which has now led […]

Florida has recently taken a significant step forward in the field of healthcare by enacting Senate Bill 1768, a progressive measure aimed at expanding access to innovative treatments and improving patient outcomes. Stem cell therapy, already FDA-approved for conditions like leukemia and neurological disorders, is now being further integrated into healthcare practices in the state. […]

In the world of oncology, advancements go beyond the development of new drugs. True innovation in cancer care involves collaborative efforts to eliminate barriers to treatment access. Experts at the Institute for Value-Based Medicine session in Arlington, Virginia, emphasized the importance of strategic partnerships between oncologists and pharmacists in addressing operational and policy obstacles that […]

In the realm of cancer therapy, CAR T-cell treatment offers immense promise but also poses significant challenges, particularly in patients with high-risk profiles. Bridging strategies, such as the utilization of talquetamab, a bispecific antibody, are emerging as crucial tools to enhance the safety and efficacy of CAR T-cell therapy for multiple myeloma patients. Dr. Binod […]

Nurse practitioner Beth Faiman provides insights into the essential nursing strategies for monitoring, assessing, and handling toxicities associated with talquetamab in multiple myeloma patients. Talquetamab, also known as Talvey, is a bispecific antibody approved by the FDA for treating multiple myeloma after the failure of four or more prior lines of therapy. Faiman emphasizes the […]

In the realm of multiple myeloma treatment, the spotlight is on talquetamab as a potential “bridge” therapy preceding CAR T-cell treatment. Dr. Binod Dhakal, from the Medical College of Wisconsin, sheds light on a clinical study exploring this novel approach. The study’s focus lies on using talquetamab to manage the disease in patients with late […]

New advancements in oncology, particularly in treatments like bispecific antibodies and chimeric antigen receptor T-cell therapy, are reshaping patient care and driving a potential shift towards outpatient settings within the specialty. Experts at a session presented by The American Journal of Managed Care highlighted the need for robust infrastructure and comprehensive education to support the […]

In the realm of rheumatology, the importance of infection prevention cannot be overstated, with the complex interplay of immunomodulatory therapies, patient risks, and the continuous influx of misinformation posing significant challenges. Rheumatologists like Leonard H. Calabrese stress the critical need for a deep understanding of available infection prevention tools, given the broad spectrum of immunosuppressive […]

CAR T-cell therapy has transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM) with therapies like cilta-cel and ide-cel showing significant improvements in patient outcomes. However, challenges such as lengthy manufacturing and wait times, especially for rapidly progressing patients, pose significant risks, with up to 10% not reaching CAR T infusion. Patients with high disease […]

In the realm of oncology, numerous clinical trials are making significant strides, targeting a wide range of cancers from blood cancers to solid tumors. This week, several biopharma companies have unveiled key trial milestones, showcasing the industry’s dedication to advancing treatment options for patients facing various types of cancer. One notable achievement comes from SynOx […]

The Fraunhofer Cluster of Excellence Immune-Mediated Diseases (CIMD) is at the forefront of developing personalized therapies for immune disorders through interdisciplinary collaboration. By bridging the gap between drug research and patient care, the CIMD aims to create innovative solutions for healthcare. Bringing together expertise from Fraunhofer institutes such as the Institute for Translational Medicine and […]

Anocca, a Swedish biotechnology firm, has successfully raised approximately $46 million to support the early-stage clinical trials of their non-viral gene-edited TCR-T cell therapy, VIDAR-1, targeting mutant KRAS in pancreatic cancer. This funding will not only fuel the clinical trials but also drive forward the company’s preclinical pipeline, showcasing a significant step towards combating this […]

Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics (GBT) in 2022 has not yielded the expected results, as the Phase III trial of inclacumab, an investigational P-selectin blocker for sickle cell disease, failed to meet its primary endpoint of reducing vaso-occlusive crises (VOCs) over a 48-week period. With disappointing outcomes in both the THRIVE-131 trial […]

As the landscape of cancer treatment evolves with T-cell engager therapies branching out from hematologic malignancies to solid tumors, the importance of nurses and advanced practice providers (APPs) in navigating the spectrum of immune-related toxicities cannot be overstated. At the 2025 Immune Cell Effector Therapies (ICE-T) Conference, experts shed light on the risks associated with […]

A groundbreaking development in the field of multiple sclerosis (MS) treatment has emerged with the administration of an “off-the-shelf” CAR T-cell therapy known as azercabtagene zapreleucel (azer-cel) to a patient with MS. This innovative approach involves utilizing genetically engineered T-cells from healthy donors to target the immune cells responsible for inflammation and damage in MS. […]

Lineage Cell Therapeutics, a prominent biotechnology company specializing in cell-based therapies for severe diseases, recently disclosed its financial performance for the second quarter of 2025. The company’s GAAP revenue in Q2 2025 doubled compared to the same period in 2024, surpassing analyst projections significantly. Collaboration income under GAAP also saw a doubling from Q2 2024 […]

Bispecific antibodies have emerged as a pivotal addition to the therapeutic armamentarium for specific lymphomas, showcasing their evolution from third-line single agents to potential combination therapies in earlier treatment lines. Particularly significant is their role as a viable option for patients who experience relapse post CAR T-cell therapy, a cohort confronted with limited treatment alternatives. […]

Human Stem Cell-Derived Neurons Repair Circuits and Restore Neural Function Recent research led by S.Z. and Y.C. focuses on the transplantation of human embryonic stem cell (hESC)-derived neurons into a mouse model of Parkinson’s disease (PD) to investigate the repair of damaged neural circuitry. The study involved the transplantation of midbrain dopamine (mDA) or cortical […]

Cryogenic logistics in Lapland involves the intricate science of transporting liquefied gases at extreme cold temperatures. This field is crucial for various industries like cell and gene therapy, cryopreservation, and space travel, where maintaining precise temperature conditions is paramount. Understanding the principles behind cryogenics and the technology used in cryogenic systems is essential to ensure […]

Exosomes, the microscopic messengers in the realm of therapeutic science and cell therapies, have been gaining significant attention for their potential in supercharging healing and regeneration processes. These tiny vesicles, secreted by cells, are known to carry a cargo of proteins, lipids, and nucleic acids, playing a crucial role in intercellular communication and influencing various […]

Lifileucel, a tumor infiltrating lymphocyte therapy, presents a promising option for patients with advanced melanoma who have limited treatment choices post-immune checkpoint inhibitor progression. Dr. Barbara T. Ma shared insights on the efficacy of lifileucel during a recent Community Case Forum meeting in New York City. This therapy involves lymphodepleting chemotherapy and has shown significant […]

CAR T-cell therapy has revolutionized the approach to treating relapsed or refractory large B-cell lymphoma, providing a beacon of hope for sustained remission and even potential cures in select patient populations. The long-term data from pivotal trials paint a promising picture, with approximately 35% of patients experiencing durable responses, hinting at the possibility of complete […]

Emily Whitehead, who was successfully treated for leukemia at the age of 7 through CAR T-cell therapy, recently visited Fargo to meet with researchers who played a key role in developing the life-saving treatment. It is a rare opportunity for cancer researchers to interact with a patient who has been cured and is alive today […]

Cellipont Bioservices, a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell therapies, has expanded its partnership with CellVax Therapeutics Inc. to advance the development of personalized immunotherapy for gastrointestinal cancers. The collaboration includes manufacturing support for FK-GI101, an autologous cell-based immunotherapy targeting gastric, pancreatic, and colon cancer. FK-GI101 utilizes CellVax’s proprietary platform, which […]

Verismo Therapeutics, a clinical-stage CAR T company, has once again been recognized as one of the Philadelphia Business Journal’s Best Places to Work for the third consecutive year. This prestigious award highlights the company’s commitment to fostering a positive and engaging workplace culture, attracting top talent, and enabling its team to develop transformative therapies for […]

In a significant development, early data from the first human stem cell therapy trial show promise in potentially advancing Alzheimer’s care by not only slowing the disease but also aiding in the brain’s self-healing process. The Phase 1 study’s primary goal is to establish a recommended dosage for a potential Phase 2 trial. As Regeneration […]